The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines

Pathology

Volumn 44, Issue 6, 2012, Pages 547-551

  Yuan, Heng Heng ^a   Han, Yu ^a   Bian, Wei Xin ^b   Liu, Lei ^a   Bai, Yu Xian ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Hospital of Heilongjiang Province   (China)

Author keywords

Cetuximab; Colon cancer; Drug combinations; Epidermal growth factor receptor; Gefitinib

Indexed keywords

EID: 84866921118     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835817a2     Document Type: Article

References (24)

1. Yarden Y, Sliwkowski M. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
2. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 2001; 19: 41-4.
3. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20: 1-13.
4. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-99.
5. Huang S, Armstrong EA, Benavente S, et al. Dualagent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64: 5355-62.
6. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority singleagent receptor targeting. Clin Cancer Res 2004; 10: 6487-501.
7. Fischel JL, Formento P, Milano G. Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. Br J Cancer 2005; 92: 1063-8.
8. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
9. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects ofmultiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
10. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-40.
11. Chan KC, Knox WF, Gee JM, et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 2002; 62: 122-8.
12. Ng SSW, Tsao MS, Nicklee T, et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002; 1: 777-83.
13. Lee JC, Wang ST, Chow NH, et al. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002; 38: 1065-71.
14. Tebbutt NC, Cattell E, Midgley R, et al. Systemic treatment of colorectal cancer. Eur J Cancer 2002; 38: 1000-15.
15. Fan Z, Lu Y, Wu X, et al. Antibody-induced epidermal growth factor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994; 269: 27595-602.
16. Naramura M, Gillies SD, Mendelsohn J, et al. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993; 37: 343-9.
17. Anido J, Matar P, Albanell J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003; 9: 1274-83.
18. Moasser MM, Basso A, Averbuch SD, et al. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61: 7184-8.
19. Moulder SL, Yakes M, Muthuswamy SK, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/ Neu(erb-2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61: 8887-95.
20. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
21. Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs 2002; 11: 837-49.
22. Thomas SM, Grandis Jr. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004; 30: 255-68.
23. Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001; 21: 499-512.
24. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic Med Chem Lett 2001; 11: 1911-4.